Suppr超能文献

接受胰肾联合移植的免疫抑制受者1型糖尿病复发的危险因素

Risk Factors for Type 1 Diabetes Recurrence in Immunosuppressed Recipients of Simultaneous Pancreas-Kidney Transplants.

作者信息

Vendrame F, Hopfner Y-Y, Diamantopoulos S, Virdi S K, Allende G, Snowhite I V, Reijonen H K, Chen L, Ruiz P, Ciancio G, Hutton J C, Messinger S, Burke G W, Pugliese A

机构信息

Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, Miami, FL.

Department of Pediatrics, Leonard Miller School of Medicine, University of Miami, Miami, FL.

出版信息

Am J Transplant. 2016 Jan;16(1):235-45. doi: 10.1111/ajt.13426. Epub 2015 Aug 28.

Abstract

Patients with type 1 diabetes (T1D) who are recipients of pancreas transplants are believed to rarely develop T1D recurrence in the allograft if effectively immunosuppressed. We evaluated a cohort of 223 recipients of simultaneous pancreas-kidney allografts for T1D recurrence and its risk factors. With long-term follow-up, recurrence was observed in approximately 7% of patients. Comparing the therapeutic regimens employed in this cohort over time, lack of induction therapy was associated with recurrence, but this occurs even with the current regimen, which includes induction; there was no influence of maintenance regimens. Longitudinal testing for T1D-associated autoantibodies identified autoantibody positivity, number of autoantibodies, and autoantibody conversion after transplantation as critical risk factors. Autoantibodies to the zinc transporter 8 had the strongest and closest temporal association with recurrence, which was not explained by genetically encoded amino acid sequence donor-recipient mismatches for this autoantigen. Genetic risk factors included the presence of the T1D-predisposing HLA-DR3/DR4 genotype in the recipient and donor-recipient sharing of HLA-DR alleles, especially HLA-DR3. Thus, T1D recurrence is not uncommon and is developing in patients treated with current immunosuppression. The risk factors identified in this study can be assessed in the transplant clinic to identify recurrent T1D and may lead to therapeutic advances.

摘要

1型糖尿病(T1D)患者接受胰腺移植后,如果有效进行免疫抑制,据信同种异体移植中很少会出现T1D复发。我们评估了223例同时接受胰腺-肾脏同种异体移植患者的T1D复发情况及其危险因素。经过长期随访,约7%的患者出现了复发。比较该队列随时间采用的治疗方案,未进行诱导治疗与复发相关,但即使在包括诱导治疗的当前方案下也会出现这种情况;维持治疗方案没有影响。对T1D相关自身抗体进行纵向检测发现,自身抗体阳性、自身抗体数量以及移植后自身抗体转换是关键危险因素。锌转运体8自身抗体与复发的时间关联最强且最密切,这种关联无法用该自身抗原的遗传编码氨基酸序列供体-受体错配来解释。遗传危险因素包括受者存在T1D易感的HLA-DR3/DR4基因型以及供体与受者共享HLA-DR等位基因,尤其是HLA-DR3。因此,T1D复发并不罕见,且在接受当前免疫抑制治疗的患者中也会发生。本研究中确定的危险因素可在移植诊所进行评估,以识别复发性T1D,并可能带来治疗进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdf6/5053280/7f82537968de/AJT-16-235-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验